Last reviewed · How we verify
Placebo/Galantamine (Reminyl®)
Placebo/Galantamine (Reminyl®) is a Acetylcholinesterase inhibitor Small molecule drug developed by Ludwig-Maximilians - University of Munich. It is currently FDA-approved for Mild to moderate Alzheimer's disease.
Galantamine inhibits acetylcholinesterase to increase acetylcholine levels in the brain, improving cognitive function in Alzheimer's disease.
Galantamine inhibits acetylcholinesterase to increase acetylcholine levels in the brain, improving cognitive function in Alzheimer's disease. Used for Mild to moderate Alzheimer's disease.
At a glance
| Generic name | Placebo/Galantamine (Reminyl®) |
|---|---|
| Sponsor | Ludwig-Maximilians - University of Munich |
| Drug class | Acetylcholinesterase inhibitor |
| Target | Acetylcholinesterase; nicotinic acetylcholine receptors |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Galantamine is a reversible inhibitor of the enzyme acetylcholinesterase, which breaks down the neurotransmitter acetylcholine. By inhibiting this enzyme, galantamine increases acetylcholine concentration in the synaptic cleft, enhancing cholinergic neurotransmission. Additionally, galantamine acts as an allosteric modulator of nicotinic receptors, further potentiating cholinergic signaling and potentially providing neuroprotective effects.
Approved indications
- Mild to moderate Alzheimer's disease
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Dizziness
- Headache
- Abdominal pain
- Anorexia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo/Galantamine (Reminyl®) CI brief — competitive landscape report
- Placebo/Galantamine (Reminyl®) updates RSS · CI watch RSS
- Ludwig-Maximilians - University of Munich portfolio CI
Frequently asked questions about Placebo/Galantamine (Reminyl®)
What is Placebo/Galantamine (Reminyl®)?
How does Placebo/Galantamine (Reminyl®) work?
What is Placebo/Galantamine (Reminyl®) used for?
Who makes Placebo/Galantamine (Reminyl®)?
What drug class is Placebo/Galantamine (Reminyl®) in?
What development phase is Placebo/Galantamine (Reminyl®) in?
What are the side effects of Placebo/Galantamine (Reminyl®)?
What does Placebo/Galantamine (Reminyl®) target?
Related
- Drug class: All Acetylcholinesterase inhibitor drugs
- Target: All drugs targeting Acetylcholinesterase; nicotinic acetylcholine receptors
- Manufacturer: Ludwig-Maximilians - University of Munich — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Mild to moderate Alzheimer's disease
- Compare: Placebo/Galantamine (Reminyl®) vs similar drugs
- Pricing: Placebo/Galantamine (Reminyl®) cost, discount & access